The Centers for Medicare & Medicaid Services recently announced that they anticipate a later start date for the Increasing Organ Transplant Access Model. The agency stated that it is “continuing to work on the final rule and is consequently anticipating a later start date for the model than the proposed start date of January 1, 2025.” The mandatory payment model would test whether performance-based incentive payments paid to or owed by participating kidney transplant hospitals would increase kidney transplant access while preserving or enhancing the quality of care and reducing Medicare expenditures. In July, the AHA informed the Center for Medicare and Medicaid Innovation that the IOTA model would add unnecessary disruption and uncertainty to the transplant ecosystem, potentially incentivize sub-par matches given the heavy emphasis on volume and would be discordant with other regulatory requirements. 

"Complex (not to mention successful) payment model implementation requires significant time, resources and staffing by hospital participants," AHA wrote. "But, CMMI has proposed an IOTA start date of Jan. 1, 2025 — less than six months from now and an even briefer time from when the rule will be in its final form. It would notify participants of their mandatory participation with as little as three months’ notice. Given the organ transplant system’s transformation already occurring as mentioned above, this aggressive timeline is untenable."

Related News Articles

Headline
The AHA today urged the Medicare Payment Advisory Commission to update payment recommendations for hospitals, post-acute care facilities and physicians in…
Headline
The AHA's Advancing Health podcast recently celebrated the end of 2024 by releasing highlights from some of its most popular episodes of the year. The roundup…
Headline
The Centers for Medicare & Medicaid Services Dec. 20 solicited an additional 10 participants for its Rural Community Hospital Demonstration program. This…
Headline
The Health Resources and Services Administration last week directed Sanofi to cease implementation of its 340B rebate proposal immediately and to inform HRSA…
Headline
The net prices of five drugs included in a new study from the Institute for Clinical and Economic Review increased without clinical justification in 2023.…
Headline
The Medicare Payment Advisory Commission Dec. 12 and 13 discussed draft payment update recommendations for 2026, which the commission will vote on in January.…